Ceftazidime in Gram-negative infections: three case reports

Area of Science:

• Infectious Diseases
• Pharmacology
• Critical Care Medicine

Background:

• Serious Gram-negative bacterial infections pose significant therapeutic challenges.
• Ceftazidime is a third-generation cephalosporin with broad-spectrum activity against Gram-negative bacilli.
• Combination antibiotic therapy is often employed for severe infections.

Observation:

• Three patients with severe Gram-negative infections were treated.
• Cases included Enterobacter cloacae meningitis, Pseudomonas aeruginosa mediastinitis, and Pseudomonas aeruginosa pneumonia.
• Treatment involved ceftazidime in conjunction with gentamicin.

Findings:

• Ceftazidime and gentamicin combination therapy resulted in clinical improvement in all three patients.
• Rapid clearance of Gram-negative bacilli from infected sites was observed.
• No significant hematological or biochemical abnormalities were attributed to ceftazidime.

Implications:

• Ceftazidime, when combined with gentamicin, demonstrates efficacy in treating severe Gram-negative infections.
• This combination therapy offers a viable treatment option for challenging infections like meningitis, mediastinitis, and pneumonia.
• The safety profile of ceftazidime in this context appears favorable, with no drug-related abnormalities detected.